| DESCRIPTION |
is a potent activator of PPAR alpha, a moderate activator of PPAR delta and poor activator of PPAR gamma. Currently we are pursuing advanced stage pre-clinical development for this compound. Pharmacologically, DRL-11605 demonstrated high potency for triglyceride lowering activity, HDL elevating and overall antihyperlipidemic effect than currently available fibrates. It also exhibits significantly higher anti-atheorsclerotic activity, glucose lowering and insulin sensitizing activity as compared to Fibrates. DRL-11605 has significantly less PPAR gamma activating properties. It's body weight reducing and overall management of Metabolic Syndrome is significantly better than Sibuteramine in both genetic and diet induced obese animal models
|